Re: Farmas USA
DVAX
I expect positive results from this trial. An earlier Phase III trial produced encouraging results but was not big enough for the FDA to approve this vaccine. William Blair recently put out a note on Dynavax noting they believe that HEPLISAV-B has an 80% chance of approval and the compound should see peak sales of $600 million annually. Obviously if approved, this would be an absolute game changer for the company and the stock. William Blair also has a $42.00 a share price target on Dynavax.
Cowen & Co. is even more positive with a $60.00 a share price target noting that the potential of HEPLISAV - B is worth more than the price of the stock.
However, there is more to Dynavax than just HEPLISAV - B. William Blair actually believes its early stage compound SD-101 could be even more potentially lucrative than HEPLISAV - B. SD-101 is a proprietary TLR9 agonist designed to elicit a potent and focused immune response to cancer.